Organogenesis Q4 Sales Soar 78% to $225M, 2026 Revenue Set to Decline 25-38%
Organogenesis delivered Q4 net product revenue of $225.1 million, up 78% year-over-year and 50% sequentially, with operating income climbing to $63.3 million and advanced wound care sales rising 83%. The company projects full-year 2026 revenue to decline 25%–38% due to near-term market disruptions from recent CMS policy changes.
1. Record Q4 Performance
Organogenesis reported net product revenue of $225.1 million in Q4 2025, marking a 78% increase year-over-year and 50% sequential growth. Operating income rose to $63.3 million from $10.2 million a year earlier, while advanced wound care revenue spiked 83%, driving gross profit to 78% of net product revenue.
2. 2026 Outlook and CMS Disruption
Management attributed the strong quarter to a favorable shift in product mix but warned that recent CMS reimbursement policies and withdrawal of LCD coverage have created clinician confusion. As a result, Organogenesis forecasts full-year 2026 revenue declines of 25%–38%, with a 50% drop in Q1 and gradual improvement throughout the year.
3. Strategic Initiatives and Financial Position
The company is expanding its Smithfield, Rhode Island facility to scale manufacturing for Apligraf, PuraPly AM, Dermagraft and new burn treatments, and expects to complete its ReNu rolling BLA submission in H1 2026. Organogenesis finished 2025 with $94.3 million in cash and no debt, positioning it to pursue growth initiatives.